(RTTNews) - Intra-Cellular Therapies Inc. (ITCI) said that it has priced its underwritten public offering of 9.52 million shares of its common stock at a public offering price of $42.00 per share.
All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $400.0 million before deducting underwriting discounts and commissions and offering expenses.
Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1.43 million shares on the same terms and conditions. The offering is expected to close on January 7, 2022.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
